GLP-1
GLP-1
SaveGlucagon-like peptide-1, an endogenous incretin hormone secreted by intestinal L-cells in response to food intake. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety.
Quick verdict
The physiological hormone that all GLP-1 receptor agonist drugs are designed to mimic. Native GLP-1 has a half-life of only 2–3 minutes due to rapid DPP-4 degradation.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
GLP-1 physiology is extremely well characterized. Infusion studies confirm glucose-dependent insulinotropic effects, appetite suppression, and gastric emptying delay. The incretin effect accounts for roughly 50–70% of postprandial insulin secretion. Deficient GLP-1 signaling contributes to type 2 diabetes pathophysiology.
Benefits
- Central role in glucose homeostasis and the incretin effect
- Well-characterized appetite and satiety signaling
- Foundation for the entire GLP-1 RA drug class
Dosage notes
Not used as a therapeutic agent. Research infusions used 0.5–1.5 pmol/kg/min IV.
Side effects
- Nausea at supraphysiological concentrations
- Transient hypoglycemia risk with exogenous insulin
Who should be cautious
Native GLP-1 is not used therapeutically due to its ultra-short half-life. Continuous IV infusion has been used in research settings only.
What this page cannot tell you
Understanding GLP-1 physiology is well established, but translating endogenous hormone biology to exogenous drug effects involves important pharmacological differences.
Leaderboard scores
- Weight loss50
Write a review
Sign in to write a review.